https://cms.megaphone.fm/channel/NPTNI5868741090 en Copyright 2026 Inception Point AI Discover how tirzepatide became the first FDA-approved drug for obstructive sleep apnea, offering hope to millions struggling with CPAP machines. Julia Cartwright investigates the science, patient experiences, and clinical implications of this breakthrough treatment that goes far beyond simple weight loss. For more content like this, visit QuietPlease.ai This content was created in partnership and with the help of Artificial Intelligence AI. https://megaphone.imgix.net/podcasts/ccf29cbe-4da4-11f1-b0c2-bbc9fd99871a/image/b41eca1c15deda07433c8bc6f537ee76.jpg?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress https://cms.megaphone.fm/channel/NPTNI5868741090 no episodic Inception Point AI Discover how tirzepatide became the first FDA-approved drug for obstructive sleep apnea, offering hope to millions struggling with CPAP machines. Julia Cartwright investigates the science, patient experiences, and clinical implications of this breakthrough treatment that goes far beyond simple weight loss. For more content like this, visit QuietPlease.ai This content was created in partnership and with the help of Artificial Intelligence AI. Quiet. Please info@inceptionpoint.ai https://player.megaphone.fm/NPTNI6866840164 Join Julia Cartwright as she explores the groundbreaking approval of GLP-1 drugs for sleep apnea treatment, a potential game-changer for thirty million Americans frustrated with traditional CPAP therapy. Discover the real science, patient outcomes, and what this breakthrough means for anyone seeking alternatives that actually work. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. Tue, 07 Apr 2026 03:09:29 -0000 trailer Inception Point AI Join Julia Cartwright as she explores the groundbreaking approval of GLP-1 drugs for sleep apnea treatment, a potential game-changer for thirty million Americans frustrated with traditional CPAP therapy. Discover the real science, patient outcomes, and what this breakthrough means for anyone seeking alternatives that actually work. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. 32 https://player.megaphone.fm/NPTNI2040702785 Join host Julia Cartwright as she explores tirzepatide's groundbreaking FDA approval for obstructive sleep apnea in adults with obesity. We discuss clinical trials showing remarkable AHI reductions, why CPAP adherence fails millions, the drug's multi-pathway mechanisms, and what this pharmaceutical option means for personalized sleep medicine treatment. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. Tue, 07 Apr 2026 03:09:27 -0000 full Inception Point AI Join host Julia Cartwright as she explores tirzepatide's groundbreaking FDA approval for obstructive sleep apnea in adults with obesity. We discuss clinical trials showing remarkable AHI reductions, why CPAP adherence fails millions, the drug's multi-pathway mechanisms, and what this pharmaceutical option means for personalized sleep medicine treatment. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. 1474 https://player.megaphone.fm/NPTNI9065697590 Host Julia Cartwright explores groundbreaking research on GLP-1 drugs and sleep apnea, revealing how medications like tirzepatide work beyond weight loss through brain receptors, anti-inflammatory effects, and metabolic improvements. Drawing on SURMOUNT-OSA trials and emerging science, she explains why these multi-pathway treatments are revolutionizing our understanding of obstructive sleep apnea as a whole-body condition. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. Tue, 07 Apr 2026 03:09:22 -0000 full Inception Point AI Host Julia Cartwright explores groundbreaking research on GLP-1 drugs and sleep apnea, revealing how medications like tirzepatide work beyond weight loss through brain receptors, anti-inflammatory effects, and metabolic improvements. Drawing on SURMOUNT-OSA trials and emerging science, she explains why these multi-pathway treatments are revolutionizing our understanding of obstructive sleep apnea as a whole-body condition. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. 1474 https://player.megaphone.fm/NPTNI9774778628 Host Julia Cartwright explores groundbreaking research on GLP-1 drugs and sleep apnea, revealing how medications like tirzepatide work beyond weight loss through brain receptors, anti-inflammatory effects, and metabolic improvements. Drawing on SURMOUNT-OSA trials and emerging science, she explains why these multi-pathway treatments are revolutionizing our understanding of obstructive sleep apnea as a whole-body condition. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. Tue, 07 Apr 2026 02:30:45 -0000 full Inception Point AI Host Julia Cartwright explores groundbreaking research on GLP-1 drugs and sleep apnea, revealing how medications like tirzepatide work beyond weight loss through brain receptors, anti-inflammatory effects, and metabolic improvements. Drawing on SURMOUNT-OSA trials and emerging science, she explains why these multi-pathway treatments are revolutionizing our understanding of obstructive sleep apnea as a whole-body condition. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. 1474 https://player.megaphone.fm/NPTNI3026658729 Join Julia Cartwright as she explores the groundbreaking FDA approval of tirzepatide (Zepbound) for obstructive sleep apnea—the first medication ever approved for this condition. We dive into the SURMOUNT-OSA trials, examining how this weight-loss drug reduced breathing interruptions and eliminated symptoms in 50% of participants, offering new hope beyond CPAP. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. Tue, 07 Apr 2026 02:30:38 -0000 full Inception Point AI Join Julia Cartwright as she explores the groundbreaking FDA approval of tirzepatide (Zepbound) for obstructive sleep apnea—the first medication ever approved for this condition. We dive into the SURMOUNT-OSA trials, examining how this weight-loss drug reduced breathing interruptions and eliminated symptoms in 50% of participants, offering new hope beyond CPAP. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. 1419